Projects
![]()
No projects found
Investors
New
DAO Treasuries
DATs
Lend / Borrow APRs
Chains
Categories
Spaces
DeSci Mic 🎙️ Deep Dive into Muhdo
Recorded: Oct. 9, 2024 Duration: 0:57:31Space Recording
Full Transcription
Thank you. Music Hello. Hey, hey, hey, everyone.
Hello. Hey, everyone. Welcome back this week. I'm slightly losing my voice. I've been at ZK Summit here in Lisbon.
And, you know, I've just been finding out I'm having a lot of loud events where I'm having to project my voice.
I'm having a lot of loud events where I'm kind of having to project my voice.
So with that said, you know, we've got a great episode with some fantastic guests this week.
You know, in case my voice gives out, I'm going to quickly hand it over to Aaron McGinnis,
who, you know, is behind the Desai Mike account this week.
And yeah, welcome back, everyone.
Please take it away, Aaron. mic account this week and uh yeah well welcome back everyone please take the way around
that's a bummer your voice is going out because mine is as well so it's hoping at least between
the two of us we were gonna have one solid voice in place but luckily we have some super awesome
guests on this week and they will be sharing all of the amazing things they've been up to over at
budo and um everything they've been working on over the past several years and where they're
moving forward to they have a bunch of super exciting stuff on the roadmap so uh pumped to
have them on this week um and with that would love to hand it over to the team
to introduce yourselves and give kind of a high level overview of um what you're building
maybe john not sure who's behind the primary account right now awesome hi yeah i'm john i'm the cmo of moodu uh we've got sam who's our md of moodu
and then we've got james our genomics and neutrinox director on the main account as well
i think he's just there he is he's back up sam if you want to request to speak on stage as well man that would be great if you could let him up
guys
yeah I tried to add him
before but
X or Twitter might be
might be preventing us
from so much cool
stuff to be shared
so in the meantime
okay maybe he can be added
I'll keep inviting but So, in the meantime, okay, maybe he can be out of now.
I'll keep inviting, but in the meantime, John would love for you to... Sam, we got you. Wonderful. Welcome.
Yeah. Hi, Erin. How are you doing?
Sorry, I'm not very good on computers, so I was struggling to get it turned on.
How are you doing? You okay?
Yes, welcome. Glad to have you up here.
Cool. Yeah, well, look, I don't know if you want to start from talking a little bit about the science and the epigenetic side of things and a bit about how we came to this transition into Web3.
I thought that might be quite a good place to start. James has been, you know, he's one of the founders of Moodoo.
He's been involved from day one.
So I think it'd be a great place to start, James,
if you want to kind of give everybody a bit of background on Moodoo,
the kind of stuff, you know, we've been researching
and the kind of things that we're doing from a, you know,
from the supplement and the research side of things.
And then I can maybe kind
of bring it all together and explain the kind of web 3d side aspect of the project would that be a
good way to start yeah that sounds fantastic cool james over to you I think we might have
technical issues
Sam do you want to kick off
or not
yeah no problem at all
we obviously had a conversation the other day
so I don't want to bore you going over all the same stuff again.
I thought it would be quite interesting for you to kind of get some more details
on the epigenetic side.
But, yeah, I'll give you guys a bit of history to Moodoo.
We've been around since 2017.
The business has been mainly B2B and research-focused.
We've developed 40 health apps for white label partners over the years.
We've built a clinical platform that's used by over 350 hospitals and clinics worldwide now.
We've worked with massive companies like Nestle, Aon, Phagron Pharma, Mercer, Marsh, Centrica.
So our epigenetic science has been kind of validated both commercially and by academia
we've worked for a long time with king's college london and national university of singapore
i mean for the for the sake of people that may eventually hear this that aren't so into dsai
no just the basics of you know what we do as a core technology is epigenetics.
By analysing your epigenetic markers, we can understand how your lifestyle and environmental factors are influencing your genes.
And this then allows us to track how your cells are ageing and how your genes are functioning, providing you with personalised, actionable steps to improve your health and well-being at a cellular level.
So that's kind of where we've been focused over the last seven, eight years. And what we're doing
now is we're integrating our epigenetics and research platform with blockchain. We're building
a new AI. And the aim is to create a web 3 ecosystem where our epigenetics technology can
empower businesses to personalize their healthcare products and also consumers to purchase personalized
healthcare products doing that in web 3 obviously makes the most sense you know we want to build
something that's super transparent um you know web 3 is the
future in that regard so what we have is we kind of have a blockchain as our foundation for the
ecosystem um it's already built it's a test net now it's a simple evm layer one proof of authority
model and it's been designed not to be the kind of next Solana or something like that. It's been designed to meet the needs of our consumers, but also partners that want to work with us, access our epigenetics platform, our research platform. DSI kind of collaborative approach to sharing customers, sharing data, research, cross-selling
products to each other's communities, opening up new revenue streams for each other, you know,
and being able to track those referrals and rewards to ensure that everyone benefits from
the value that they create. So, you know, the blockchain just makes that so easy to do.
You know, from the consumer side, what we're building is we're building a healthcare brand primarily.
There is obviously we've got all the science and the research
and all of these things that feed into it.
But ultimately, we're building a healthcare brand.
And for us, certainly post-COVID, you know, you've seen it now,
the trends towards preventative health
and people looking at alternative ways of looking after themselves has really kind of just blown up.
It's definitely the future. The technology hasn't existed until now to do it.
So we're very fortunate to kind of be trailblazers in this field.
And we're using the blockchain to add value to consumers in as many ways as we
possibly can, not just sharing rewards for paying rewards for sharing data. You know,
we're going to be manufacturing all our own products within the ecosystem. So we'll use
the blockchain to give supply chain provenance on everything we sell, see to sale. So if you're
buying health products from us, you're going to know that absolutely every ingredient,
what's in it, where it's come from, how it was made,
why it was made, which I think is something
that should just be general practice anyway in healthcare
or any kind of products that you're putting inside your body.
But maybe we'll get there in the future.
But essentially the mission that we have here
is to create a fully
transparent platform and use our token use but web free and use these mechanisms to eventually make
premium preventative personalized health care affordable for everyone not just the one percent
like most longevity brands seem to be um kind of. And I think, you know, when you look at everything that's just gone on with 23andMe,
people are realizing more and more as these things happen that they should have control over their health data.
And so with us, we've never sold data. We've got we've done 65,000 tests.
We've never, ever sold that data. it's only ever been used for our own
internal research which is why we now have a pipeline of products that we're going to launch
that have eight years of science backing them and i can't see if james is on the call but if he is
i'll get him to go into some of the more detail on this because it's super exciting stuff these
products we're going to launch on our first consumer application
on the chain at the start of next year, the Moodoo Hub.
It's a hyper-personalized, all-in-one wellness platform
powered by an AI health coach that helps you understand
all these complicated and complex health assessments.
It then offers you actions to take. You can now
buy personalized health products directly in the application, and that AI will track your progress
through user engagement and repeat testing. One of the reasons why we're doing this project is to
actually have our own lab set up, and the aim is to make, to be able to give away these expensive tests for free
to people that subscribe to our supplements.
So, you know, we're trying to create
as many win-wins as possible.
And I think that's what's really exciting
about the platform that we're building.
We've got six applications that are building on our chain
that are all real world consumer applications that focus on
different areas of health and different demographics so not only have we got our own
tech stack in with the epigenetics and the bioinformatics and that we're now bringing in
partner brands that want to move into personalization but also be able to track and
measure the effects that their products are having on people at a cellular level and as we grow the ecosystem you know we create a slightly
different model to the traditional DAO model you know the traditional DAO model tends to pick a
theme and you raise the money to invest in research we've already done that research to prove that these products work
so the way that we will create our flywheel to keep funding innovation and research downstream
rather than doing a standalone DAO offering is we that our DAO invests in products in in revenue
generating operations right so our supplements our tests
all of these different things they generate revenues and we have a rev model within the
dow and and that allows money coming from products being sold to come back into the ecosystem so
we're actually going to be funding research for future products and services through revenues
that our existing products and services
are generating so that will aim that gives us a really sustainable long-term business model
and again you know using web3 for all of the best reasons not just as you know as a gimmick
is something that you know we feel that our brand definitely is aligned with and you know having our own lab
our own supplement set up means that we can offer the best products at the best price and still
pump money into the ecosystem and have a profitable business and it's about finding balance between
having a sustainable model you know and obviously being able to incentivize all of the participants. So,
you know, that's what we're trying to do, you know, with regards to the D-Sci community and
how we can kind of, you know, add value to the D-Sci community. You know, we've got this technology,
it's used, billion dollar companies use our platform, you know, without naming names,
certain companies bought other companies based on the research that we've
published so we know we've got best in class technology and we want to be able to say to
other people that are doing research on products or trying to develop products or even want to move
into kind of more precision medicine that they can come to our ecosystem use our platform and we can
collaborate in a trustless and transparent
environment where everybody who contributes to whatever that you know outcome is is rewarded
fairly um and yeah so that's kind of where we're what what we're our mission if you like i don't
know if james has come back on the line but yeah i can see he's there james oh you've you dropped
off so i wanted you to kind of give the guys a bit of the kind of the background on the line but yeah i can see he's there james oh you've you dropped off so i wanted you to kind
of give the guys a bit of the kind of the background on the science i guess i did that
bit already but maybe you could um you know tell them a little bit about the kind of depth
of the products and stuff that we've been working on and some of the stuff like that
yeah of course can you hear me all right? Perfect. Lovely. Okay. Without giving too much
of our secret sauce away. So the product's been in development for, well, since 1066 really,
it's been in development for the last seven years and it's unique in a number of ways. And I'll just
give you a bit of an introduction. So as we age, our ability to maintain our health and DNA repair
gets a lot worse, unfortunately, as we probably already guessed. And this makes the vitamins and minerals in the aging process even more important than when we
were younger. And we've got nutrients like the usual things that most people have heard of,
B vitamins, magnesium, zinc, and folate. But these are actually really essential for DNA methylation.
And DNA methylation is a process that is crucial. It's fundamentally crucial to life. If we didn't
have DNA methylation, we wouldn't last very long.
It actually helps to regulate gene expression, and it's actually crucial for cellular aging.
So without adequate methylation, the body actually struggles to repair DNA damage,
which can lead to accelerated aging and obviously lead to a lot of illnesses as well.
So the aim of the supplement, well, there's a few aims, but simplistically it's to help slow the aging process from a fundamentally important vitamin
and mineral profile. So you see a lot of supplements and they've got a couple of vitamins
in, a couple of minerals in, but normally the bioavailability of those vitamin and minerals
are quite poor. The dosages are quite poor. So we're trying to maximize them as best as we can we also need to
provide the nutrients for optimal methylation with specific nutrients and i'll run through
a few of these in a bit because having these nutrients will obviously maintain youthful gene
activity and help promote longevity as well the methylation cycle in itself i'd be here for for a
couple of hours explaining the various
nutrients if we went around the whole thing, but there's two main crucial areas that you need to
look at for methylation. So you've got methyl donors, which are nutrients that are capable
basically of donating a methyl group and making it more active. So there's things like choline
that most people probably would have heard of in most brain supplements. They give you a bit of a spark and then they rev you up.
Then we've got one called seamy, which is fundamentally important to methylation.
And you won't see this in probably, I'd say, 99% of longevity supplements
because it's quite a unique nutrient.
Then we've got B12.
There's different types of B12.
I'm quite a stickler for getting the right one. We need the methylated cobalamin. It's a lot more bioavailable, does a lot more things in the body compared to the usual B12 that most people use, which is cyanocobalamin, which is not very nice at all. It's actually synthesized from raw sewage, so we probably don't want to use that one.
It's actually synthesized from raw sewage, so we probably don't want to use that one.
Then we've got another group of nutrients called methyl conserving nutrients,
that basically means that they require a lot of methylation to be made.
So if you actually give the body them directly, it helps the process.
And there's one called creatine that most people would have heard of,
but mainly from a gym perspective, helping the energy in the gym,
improving muscle performance, and so on and so forth. But creatine is actually fundamentally important to the aging process
and methylation. And then we've got carnitine. A lot of people take that to try and lose weight.
So there are a couple of nutrients in there. Then we've got, I'd say, probably around 10 nutrients
that we've seen from our own research. And I don't know how many thousands of epigenetic
samples and the research study now we have, but they show clear correlations for people with have actually having a lower epigenetic
biological age so we've popped them in there as well and in relation to our main supplement
and again this is quite unique because when most people take a supplement they'll either take it
in the morning or take it in the evening but. But we split it into two to work with your circadian rhythm,
to work along with the body's 24-hour cycle.
So we've got a powder during the day that will basically encourage you to drink more water.
It's an extensive multivitamin, antioxidant.
There's various things in there called senolytics and polyphenols
and various other things that help promote healthy methylation and gene expression.
And then uniquely, and I'm quite proud of this one, our nighttime formulation will come in
capsule form. You don't want to be drinking a lot of fluids in the evening, otherwise you'll be
going up to the toilet all evening and you won't be getting a restful sleep. Now, crucially with
the formulation in the evening, we've harnessed specific nutrients that target specific genes
associated with sleep. And there's a whole variety of genes associated with sleep and there's a whole variety of genes
associated with sleep two of the main ones are called clock ironically and one called GABA RA2
in relation to the GABA pathways and helping you to relax so we've again got key nutrients in there
and cofactors that will help you unwind help you relax and help you fall asleep so that's that's
basically an overview of our supplements Sam. Cool and just to be clear that's our that's that's basically an overview of our supplements
cool and just to be clear that's our that's our law so we're launching that that product and that is backed by eight years of epigenetic research that's not the personalized products the personalized
products will come downstream when we launch the web 3 application and um and we finish our kind of
uh we get to that stage in the in the project line but we've got years of research that proves
what works and how these supplements affect genes so everything that we're going to be putting out
into the market is going to be backed by research already in our existing application our web 2 application every
recommendation and or intervention is backed by at least five peer-reviewed white papers
so you know we're sticking to the facts very much on this and everything that we do is going to be
data driven and be able you know the cool thing that the consumer is going to get from this is a
platform that they will be able through repeat testing to track measure and optimize their formulations as they go on that journey with us
and the only way that you can make that affordable is with this kind of disruptive model financing
model that we've put together and that enables us by having our own machines we're going to be able to turn the tests around
within 72 hours the industry average for dna is like four weeks so we're going to be able to give
much faster results and we're going to be able to give free tests to people when they subscribe to
their supplements so not only are you buying supplements that are designed for you, you also get that
value add of being able to track that and measure it. And I think that's what's going to really
create valuable data because, you know, DNA is kind of like a dead market now. You know,
anyone that tells you they're going to monetize your DNA data is, you know, is living in the past.
23andMe, they crushed that game. But now there's millions of people's DNA data is, you know, is living in the past. 23andMe, they crushed that game.
But now there's millions of people's DNA data available for research in the UK's biobank, for example.
You know, epigenetic data and being able to understand how all these external factors affect your genes is so valuable.
so valuable and our whole ecosystem becomes almost a live interactive science experiment
whereby we're going to have all of these different applications and be able to look at all of these
different types of demographics and how you know and and learn things in real time and having that
all on the chain you know and breaking down the barriers that academia put in place. You know, there's real, I mean, James will be able to tell you it more,
but getting papers published, getting peer reviews,
the incentive mechanisms that exist today are really backward
and make absolutely no sense.
So, you know, it's one of the things we love about what the DSI community
is doing at the moment because everybody has value in different areas and different protocols and different ways that they can contribute to this.
But I think it's probably the one sector that you're seeing real collaboration across the board because nobody's going to be able to figure it all out on their own.
And, you know, there's companies like ours you know out there and trying to do similar things and you know we we all seem to be willing to work together there's
eight billion people you know you're never going to get a bigger market than health it affects
everyone so you know trying to own that market makes no sense we're better off collaborating and
working towards value versus profit and and that's why we're doing what we're doing
because we're cutting out all the middlemen.
You know, by manufacturing everything in-house,
we can have pure accountability for the products
and that supply chain, but also cut out the middlemen.
And that's so important because most of what you pay
for pharma drugs or healthcare is commissions to people that do absolutely nothing to create those products.
So, yeah, sorry, going on a bit of a rant.
But, yeah, there's that.
We've also got a research platform now which went live in Q2.
which went live in Q2.
And that's super exciting because that now enables us
to process terabytes of health data very quickly.
And rather than giving someone that raw data,
researchers now can come and use our platform
and they can interrogate that data,
ask questions in a really easy chat GPT type way.
And we've got some really great successes already.
We've already had two major clients that are probably going to do more business for us in the next year than we've done in six just from that.
So it's exciting times for Moodoo.
You know, we've built the rocket.
We're launching, you know, we're launching in hopefully by the end of this month on TGE.
And we've got loads of exciting partnerships. We've got loads of exciting products.
You know, we are definitely going to be here for the long haul.
So, yeah, appreciate the time and the opportunity to come on here and introduce our projects to you guys.
And if you've got any questions, we'd love to answer them.
I will put a disclaimer out there now. I don't speak dev.
So please try to avoid the deep, deep, deep technical dev questions.
But yeah, happy to answer any questions about the business.
And we've got James here who has more knowledge in his head than you could
ever imagine. Amazing. Thanks so much for that overview. For everyone listening in,
if you have a question, definitely either type it down below in a reply or request the mic and
we can bring you up here to be part of this conversation.
I had a couple of questions kind of off the bat.
One would be, you've been kind of in this whole broader space for a good couple of years now working on this.
Are there any key learnings or lessons or takeaways that you've discovered over this
time that might be interesting to just highlight for others,
maybe going down other parallel paths? Well, I mean, I think, you know, when James and Nathan
started the business, they both had full heads of hair. I think it's been quite a stressful journey.
Being a new category, you know, it can be very, very expensive to create a category. So we
took the view of kind of being B2B and licensing the technology to clinics and to other people that
had customers. Just to really, you know, Erin, to your question, understand where the pain points
were and kind of learn the market before the market exploded. You know, I think thanks to Gary Brecker and, you know, all the millions that have gone
into marketing recently into kind of publicizing personalized nutrition and things like that,
you know, the market has now arrived.
You know, I think we've learned most from the consumer point of view in the sense that,
you know, once someone does take the leap to take that test
they want an immediate you know click now buy now and that was one of the things that our customers
were always pushing us to kind of put into the app um you know the testing um as an industry is slow
and you know when you're measuring epigenetics and it takes four to six weeks to get a result
by the time you get that sample you know within four to six weeks so much could have changed so you're
always playing catch up so solving those problems really are more from an efficiency point of view
James anything you know from from that you can add to that yeah I think I think you covered most
of it to be fair but I think it's the the thing that we've probably found out in relation to lab analysis and working in the real world is people want results now. We've got a culture of wanting everything the next day. And unfortunately, the speed of science sometimes, to coin a phrase, very sophisticated and complicated process. So you can't, unless you've got your own multi-hundred million pounds lab, you can't turn around the times of epigenetics extremely quickly.
I mean, we've got a lot better over the process.
So we've got us down to still the fastest out of anyone out there.
But again, it's the speed of turnaround time that's probably one of the areas.
But it's just the speed of science generally.
It's quite frustrating when you're trying to develop something that things take a long time to come into fruition sometimes.
And we've spent the best part of the last seven years heavily researching a lot of areas.
So we're ready to go now, really.
And in relation to working with a small team, I guess the benefit of the small team is we're a very focused team.
If you've got lots of pieces and cogs in the wheel,
you've got a lot of voices and can sometimes cloud the issue.
But I guess as the guys that we work with,
the rest of the team, we're very extremely focused.
And I guess that gives us the ability to move very quickly.
that gives us the ability to move very quickly.
Yeah, I think from my side as well,
looking at the market in for moving this
into like a web free ecosystem as well is,
you know, like boiling down your messages as well.
Like if you're trying to do a lot,
there's a lot of decide projects
and a lot of people in the space with blockchain and as soon as you start bringing real world and
assets and there's that cold narrative at the moment around you know rwa like there's nothing
more real than like you and your health data and your you know how you feel inside and like
and how you feel inside.
And people are sometimes afraid of that, right?
Mixing the two together puts up some red flags
and addressing those security issues,
those transparency issues,
and making sure that you've got a real robust system in place
for storage of that data
and making people feel comfortable with
how we're operating in the web3 space is really important. And speaking to other DCI projects
that are talking about monetizing consumer information and stuff, I think is something
that everyone needs to address. We've partnered with the Secret Foundation and Zero Proof Knowledge to make sure that we're adding additional layers of privacy and security.
So I think as you bring a product and a project to consumers that involve, you know, personal information and health,
having like good partnerships and good projects building with you has really helped us kind of be clear on that narrative and make people feel secure around the data that
we're looking at.
Yeah. I mean, you know, I, I,
I don't think it's an understatement to say that, you know, what, what,
what you guys are doing is, is, is revolutionary. Um, so like, you know,
fantastic work on moving the needle
as far as like personalized health.
I had a question about like adoption with like,
you know, and partnerships with clinics.
I mean, historically, it's been difficult to get,
you know, hospitals, clinics, whatnot,
to like adopt new technologies.
Just curious about like your
your your strategy for getting us as far as you did there is there anything special you did or
like this sort of like the technology speak for itself that like there's such a value out here
that you know it it's really not a hard sell i mean a lot of the business in the early days came
through academia and i think anything to do with, when you've got that seal of approval from academia that's going to help us build the US market,
who built a $7 billion a year healthcare business with over 40,000 employees.
Won't say too much at this stage because we haven't put the press release out,
but that's an example of someone that has that distribution and that network in place.
someone that has that distribution and that network in place.
We're also working with one of,
if not the biggest groups out in Southeast Asia as well.
So what we do, what we've done is kind of plug in, pop down, you know,
and taken a kind of almost partnership slash distribution approach to it.
But ultimately the, you know,
the clinics are a great place to engage the customer.
Nobody wakes up in the morning and says, hey, I need to do an epigenetics test. But when you go
into a clinic and you're doing things, I want to get a vitamin drip, I want to do this. Oh, great.
Okay. Well, why don't you take an epigenetics test and we can personalize that? So I think it's
always going to be a great place to introduce the products to the cons
to the consumer so it just made sense to kind of start off in those areas um before going direct
to consumer ourselves we wanted to kind of prove everything out uh we didn't think it would take
eight years but uh prove everything out and then go to market kind of bulletproof and
and to erin's point you know having learned from the pitfalls of others um you know we've we've
done a lot of research for supplement companies as well over the years so yeah i mean we're we're
ready to go like james says we you know we've gone through this process now and it's about monetizing all of this research to create
revenues to then drive more research into more products and services and create this
self-sustaining DeSci ecosystem. I think as well, speaking from someone who's taken the Moodoo tests
and looked into their epigenetics, there's no one that can't benefit from doing this
test whether it's finding out you know genomically why you feel tired what supplements you need to
take we all go out we buy a flash bottle or we buy the cheapest version of a vitamin and no one
really knows if you're deficient in it why why you might be deficient in it and what's going on
inside the body so i think if your product's good enough and has like an actionable event
and guidance that you can take, right, on day one,
and I think that's why it's really important for us
that we're building out this AI health coach
that's going to help deliver that information
in a really clear and transparent way.
Like there's a whole word of mouth thing as well.
Like there's no one that I know that doesn't like there's no one that that i know that doesn't
know about moodu and doesn't know that they should take this test to find out you know what's going
on and what you should be taking so you know the product stands up to the testing and then our
consumers and customers refer their friends they speak to them because everyone can get something
from this doesn't matter if you're an olymp athlete, like the ones that we've worked with, or if you're just a DJ and sitting in the dark all day, working on your computer,
playing with crypto and coding, and you're massively then deficient in vitamin D,
there's insight and there's actionable steps that you can take.
Just to add to that one final point, we're essentially giving everybody the ability to be a biohacker you know
from an application in their phone at a price everybody can afford you know and i think that's
an amazing thing because a lot of people when they look at you know some of these longevity products
are immediately excluded based on cost you know for us on our supplements you know you're looking at less to get every nutrient
your body needs you're looking at less than i think three pounds a day less than a cup of coffee
you know so you know with that's what we're you know what our mission is to make it affordable
for everyone and through this blockchain mechanism it's it enables that but anyway i'll let you go sorry you were going to say something no
hello these are cool um yeah anyone feel free to to jump in um putting the prompt out to everyone listening in, feel free to ask a question as well.
Another question I had was, you've talked a bit about collaboration and just making sure all of
this is accessible to different people. Are there any, like, ways for people building out other
projects, whether they're in more of a traditional lab, maybe they're building
out a D-side project or something else kind of in the space overall. Are there any ways that they
can collaborate with you or maybe they're just an individual person interested? What are the best
ways to get more involved if they're interested? Yeah, no, no look the b2b side of our business is still
going to exist albeit in a more advanced ecosystem so we're definitely um you know we're looking
we're we we're being approached every day by different companies that want to collaborate
on different types of research i think think epigenetics is so broad
that there's so many different areas
that we could add value to.
So 100% that will be available.
The chain, it's EVM.
You know, it's really simple stuff.
So if somebody wanted to come and build on that chain
or we bridged or we did, you know, something,
we're open to collaboration.
We just wanted to make sure that the foundation layer of the ecosystem, you know, that we
built that ourselves so that we knew it, you know, we were, it's all about accountability
and transparency.
Love that. love that uh super super aligned with i think the direction so many people listening in right now and so many other people in this space are building as well so um always love hearing that reiterated
these kind of partnerships are creating revenues for the business and for the ecosystem
as well so that that obviously right we're super excited about it but um yeah i mean there's
definitely some protocols in the dsai space that we think are really interesting and like john
alluded to we've done some partnerships with um secret and zero knowledge networks and we're
certainly trying to kind of put that infrastructure and privacy stack in place first um because it's so important um and we've already got
all the rest of the other technology already built so um so yeah the testnet's up we can share that
information with you if you haven't seen it it's running smoothly we launched a brain game to our community i think sam's microphone keeps rugging him
yeah i think so too uh can you elaborate more on the yeah so um we've seen the kind of uptake
on the ton clicker games and hamster combat, right?
And we wanted to put our own Moodoo spin on it.
So what better way to do that is that, you know, on our existing app at the moment,
we've got cognitive games that are proven with science to help improve your cognitive functions.
So we wanted to create our own Telegram version of that.
own telegram version of that so we started with a brain training game we've got weekly rewards
So we started with a brain training game.
opportunities to participate in an airdrop of the dna token every time someone generates a score
the scores tracked on our blockchain uh creates a wallet so we're strain testing and our our chain
at the moment with it we're creating new holders we're creating testing our chain at the moment with it. We're creating new holders.
We're creating excitement.
We've created a special skin for one of our partners, HashAI,
and we're doing competitions amongst their communities.
So anyone with projects and utilities that want to build
and be a part of the Moodoo ecosystem and blockchain,
or if you're just an individual that wants to play some fun brain training games,
I must say, I think the leading score
played for seven hours straight.
We did have to put some little breaks in there
to make sure that they wasn't damaging their brain
at the same time and give them a break from playing.
But yeah, come over, play the game, get involved.
The whole team are in the chat from the ceo to the
community managers we're uh we're readily available 24 7 as we uh lead forward towards
this tge at the end of the month amazing yeah terminally online founders are definitely like, you know, a show of strength, I would say in this
space. I can add a question, you know, feel free to just punt the question if it's, you know,
too early. But, you know, our audience, you know, loves to get a little bit of alpha, which,
you know, I mean, we've learned a lot your your products and and project today but just focusing a bit more on the tg is there any more alpha you can sort of
drop there like you mentioned airdrops uh what what what do you what can you share about the
form of the tg if anything will it be like the form of an airdrop liquidity bootstrapping pool
bonding curve or some other thing yeah i mean we're a mixed a 15 million
dollar funding round at the moment so we are going for it and we've got some strategic partners and
investors that are coming on board and sam alluded to some of those earlier in the in the call
that are going to help not only with our web 2 business but also the web 3 so we've got some strategic advisors
investors that have uh pledged and uh invested already that are gonna you know sit on both
side of the fence and want to come on this journey and they want to be part of a
existing business that's successful that's kind of bridging this gap to web two to web three. We are looking to integrate very shortly
with a large telemed app out in Asia
that has over 10 million users.
So we're gonna be their genomic and supplement partner
as well as the DNA token being used as a reward mechanism.
So we are like going for it, right?
We're going to turn up with a hell of a lot of users
that are from a Web2 community.
Our app's going to feel like, you know, a Web2 app.
We don't necessarily want it to feel like a crypto app.
So we want to kind of make sure that people are comfortable
and familiar with the operational side of it.
But we'll have all of the um you know web free features that communities are often fond of such as staking we've got
mechanisms to consent to earn by monetizing your your epigenetic data um what else can i drop
without spoiling anything i mean we're literally like Can I just add to it, just to go back on one bit you missed out,
the actual launch strategy,
we're just waiting to finalise.
We're pretty close to our soft cap.
So we're either going to hit our soft cap
and just go with, you know,
straight to retail for the final part,
or, you know, we will carry on
and hold out to try to fill the hard cap.
But we haven't 100% decided on that.
So probably next week, we're going to have a kind of final launch strategy
based on how things go over the next week or so.
But yeah, we're coming up to TGE pretty quick.
And that kind of final launch strategy will be announced when we are finalized it
yeah fantastic oh go on i was just gonna say yeah like the best way to keep up with it is
obviously follow us on x come over to the telegram um like i said we're in there all
the time we're constantly discussing plans and opportunities so
yeah that'll be the quickest way to to get your finger on the button
so sounds good so um you know i guess it's a call to action for the audience everybody who's going
to listen to the recording um it's an opportunity to be in um sounds like an opportunity to be in, it sounds like an opportunity to be on the ground floor of something amazing.
Yeah, you know, just want to make an open call for anyone in the audience.
You know, you've got any questions for the Moto team,
by all means, we'll request the mic, Sage.
In the meantime, you know,
just maybe a question about, like like what the nature of the, you mentioned,
you know, governance of the protocol or perhaps of the business. I was kind of unclear on that
with the governance token. And, you know, what can the DAO decide to do? And like,
whether there's like sort of like governance rails that you're thinking about to prevent things like the DAO voting to, let's say, sell everyone's data?
For example, just some out-of-left-field governance proposals and things like this.
things like this. Yeah, I think initially, for sure, like the proposals that are going to come
are going to be presented by us as a business to say, like, you know, this is what we've
been shown. This is what we'd like you to vote on. We work with a lot of academia partners,
which Sam mentioned, where we've got access to medical IP that's, you know, very close to a
commercial stage using our bioinformatics
platform to prove it out so we have a load of opportunities from that front it doesn't mean
that you know community members can't come to us and say hey like i'd love you to discuss this or
show this um and and we could you know take a look at it to to um to invest and support. We've got the MuDAO Foundation as well. So there's a lot of
value in certain epigenetic data. So at the moment, it's type 2 diabetes, the $16 billion worth of
grant funding available. So part of our revenue will go to that foundation. The foundation will work to provide free testing where we know that there's a lack of data available and there's a high financial reward.
Those funds will then come back into the ecosystem to the holders as well.
So it's looking at opportunities like that that can bring value to the wider ecosystem, that can create more products and partnerships for the Moodoo ecosystem and community.
So they'll be able to actively get involved in, yeah, supporting D-Sci projects, supporting medical IP,
supporting communities that are in need.
We want our community to feel part of what we're doing and also feel proud to be a part of what we're doing and also you know feel proud to be a part of what we're doing like we can help
really help people if you're if you're currently not going through such a good time i don't think
anyone's not been affected by let's say someone with cancer or something like that if we can
provide testings for free you know make sure those communities understand what's going on inside their
body at the genomic level help them feel the best they can be, but then also use that information to help create products for you know future people and help
prevent people getting sick in the first place. I think that's a fabulous thing to be a part of.
definitely agree uh super exciting things across the board you guys are
are working on and i think will be rolled out in the near future i pinned up above
a reply that you had posted so for anyone listening in definitely go join their telegram and get
involved with their community doesn't seem like any other questions have come through but one last
call for that for anyone that might want to come up on stage ask a question otherwise i think you
did a great job covering it maybe that's's why nobody has questions on that front.
So that's great. Yeah. And any of the builders that are out there, any other DSI projects, please get in touch.
This is obviously we want to be as collaborative as possible.
We've got access to a ton of, you know, services, information, academia partners that might be able to help.
And we might be able to help you build out the next best project as well and the next best thing so we really want to work with people in
the space so please come over say hello we won't we're not scary we're just normal people
okay and we've we've had uh one one audience member come up on stage. Ed, do you have any questions for the Moto team?
Yeah, it's interesting what you're working on.
I come from the regenerative ag community, and I was wondering,
we're looking at things like metabolomics of what we produce in foods
so that we can have a much deeper understanding in what the foods we're producing and by how they're grown.
In fact, we're even going to be able to have it at the consumer level,
so they'll know within the variation of metabolomics of what they're purchasing,
whether it be a carrot or a tomato, where it lies in that,
which seems would make it easier then when you are trying to then supplement
that. The other thing that regenerative farmers are working on is epigenetics and seeds,
because we realize epigenetics is multi-generational. And so I'm wondering how
you bring that multi-generational concept into what data you're using.
Thanks.
Awesome.
I might pass that one over to James if you've got anything to say on it or Sam.
Pretty best.
Yeah, I can touch on it briefly, I guess, because it's with epigenetics, we're still obviously fairly in our infancy.
So understandings, transgenerational epigenetic inheritance, because that's a bit of a tongue
tie, is obviously very important in trying to find out how specific traits, illnesses,
diseases, or other afflictions pass on to generation to generation.
If you look at the one instance would be the Dutch famine during the Second World War,
when the Dutch population were surrounded by the Germans that actually allowed them to have no food.
So if you look at the subsequent generations, the children and the grandchildren,
they develop such as type 2 diabetes and various other diseases and ailments. So I think in relation to where we're going with that, it looks extremely promising.
I mean, with the data, we've not looked at the data as of yet because we've been trying
to get and basically drill down what we're doing currently.
But it's definitely a path we'll probably follow on to.
I mean, we're part of the the european horizons project which looks at
outside detection so if we can probably well develop and and probably pinpoint that down
with a bit more specific details and i think transgenerational things i think will probably
be something for the not not so distant future i would think
so distant future I would think. Well we've got the congenial tests that we've that we've just
developed actually which I guess is looking at this from a from one angle whereby we you can take
two people will take a test before they get married and you'd be able to see any of the kind
of potential issues that you could have
with that child and that's something that we've done for the south asian communities that have
very high birth defects so we are definitely looking at at sort of ancestry aspects of it
but super interesting and what you you're doing i'm a big fan of kind of regenerative farming and you know um being involved in the kind of medical cannabis uh industry for for some time you know
the whole epigenetics and seeds epigenetics was that was where i first learned about epigenetics
um so super cool on on what you guys are doing
sake
well there you go sounds having technical issues
issues.
Awesome. Well, I think
it's probably
off, so I was just cursing
at my laptop,
cutting me off for the 15th time
and I thought I was off.
And when I've just logged back in for some reason,
it echoed on me again, so I heard
myself, apologies for the bad language.
I was shouting at the laptop, not you guys.
That's how we know it's time for all the things we're working on to to get out into the world and get implemented so um super excited for everything you're building
uh just in the last minute or so any hurting thoughts that you want to leave the audience
with right now i would just say stay tuned.
I think we're at the very beginning now.
Our first press release kind of announcement for Web3 was, hey, guys, Testnet's live, because we didn't want it to be the focus of what this project is.
But we've got a load of Web3 partnerships, secret, zero-knowledge network, hash AR, and and some deep in stuff that we've done
we've got some big partnerships that we're working on and you know apologies um because you know some
of the answers to the kind of launch strategy and some of the other stuff may have been a little bit
vague on the kind of dow protocols and stuff like that it is a evolving it it's a fluid, fluid thing for us right now. So we just don't want to kind of put things out there that may change.
But just stay tuned.
It's the kind of, you know, the leaving thought.
We're going to start really making a lot of noise.
We've got some great KOLs that are super into the project.
They're going to bring a lot of audience to us on Twitter.
We've just started growing our community. So you know how it is,
the kind of three weeks before the launch
is going to be real crazy.
And we've got loads of really exciting stuff
to show you guys as we go along.
New websites being built at the moment.
So hopefully in a couple of weeks,
we're going to look like a completely different company, brand, everything like that.
We'll be very much web 2, science, you know, most of the business has come through referral.
You won't recognise us in two two weeks let alone three weeks you know
really having issues with his mic but yeah please head over to uh mooduhub.com head over to our
x and over to our telegram and uh thank you all for having us today and uh yeah see you soon amazing i feel like that that could just be a cliffhanger for all of us to keep our interest
high uh and definitely hop over into the telegram follow you guys on twitter and for future
conversations in dsai come back here next week same time 4, 4 p.m. UTC, 12 p.m. Eastern Time for more conversations
on DSI. If you have a topic you would like us to discuss or something you want to share with
the DSI community, reach out to the DSI Mic account here. My co-hosts Merrick or Aaron McGinnis,
that's who's speaking behind this profile today, And we can get you scheduled in for one of the upcoming weeks.
In the meantime, keep being awesome.
Let's keep making science better and talk to you again soon.
Thanks everyone.
And thanks for coming on this week.
Thanks for having us.
Okay.
Take care.
Bye guys.
